Senior Advisor, Eli Lilly and Co.

An established pharmaceutical regulatory expert. Obtained Emergency Use Authorization (EUA) for Bamlanivimab, a Covid-19 antibody product. Invited to present the regulatory perspectives on the accelerated development of Bamlanivimab at a global forum. Providing strategic guidance to various teams on global shipping requirements and product distribution in US and global markets. Leveraged past deep quality and analytical experience to drive thorough review of submission documents to the FDA and other global regulatory authorities. Consistently reaching across boundaries to build partnerships with other regulatory scientists, technical stewards, and quality, including senior leadership.